Quantitative Hepatitis B Surface Antigen, the Trustworthy Biomarker for Functional Cure of Chronic Hepatitis B.
作者信息
Choi Jonggi
机构信息
Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
出版信息
Gut Liver. 2023 Mar 15;17(2):179-180. doi: 10.5009/gnl230070.
Abstract
摘要
相似文献
1
Quantitative Hepatitis B Surface Antigen, the Trustworthy Biomarker for Functional Cure of Chronic Hepatitis B.定量乙型肝炎表面抗原，慢性乙型肝炎功能性治愈的可靠生物标志物。
Gut Liver. 2023 Mar 15;17(2):179-180. doi: 10.5009/gnl230070.
2
Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring.利用乙型肝炎核心相关抗原检测优化治疗后监测。
Clin Mol Hepatol. 2024 Apr;30(2):293-296. doi: 10.3350/cmh.2024.0101. Epub 2024 Feb 19.
3
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers.迈向乙型肝炎病毒功能性治愈——血清病毒标志物治疗期动力学的影响
Clin Mol Hepatol. 2023 Jan;29(1):113-117. doi: 10.3350/cmh.2022.0333. Epub 2022 Oct 31.
4
Targeting liver metabolism: a pathway to cure hepatitis B virus?靶向肝脏代谢：治愈乙型肝炎病毒的途径？
Expert Rev Gastroenterol Hepatol. 2023 Jul-Dec;17(7):645-647. doi: 10.1080/17474124.2023.2226390. Epub 2023 Jun 18.
5
Genomics on the road to functional cure of hepatitis B.乙肝功能性治愈之路上的基因组学
J Hepatol. 2024 Jan;80(1):6-7. doi: 10.1016/j.jhep.2023.11.002. Epub 2023 Nov 18.
6
Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.抗病毒治疗、乙肝表面抗原血清清除及乙肝相关肝细胞癌的晚期复发
J Hepatol. 2022 Nov;77(5):1471-1472. doi: 10.1016/j.jhep.2022.07.005. Epub 2022 Jul 19.
7
Reply: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect, or residual confounding?回复：乙型肝炎肝硬化患者停止治疗的益处、真实效果还是残余混杂因素？
Hepatology. 2024 Mar 1;79(3):E97-E98. doi: 10.1097/HEP.0000000000000641. Epub 2023 Oct 20.
8
Why is the functional cure rate of young children with chronic hepatitis B receiving antiviral therapy considerably high?为什么接受抗病毒治疗的慢性乙型肝炎幼儿的功能性治愈率相当高？
Hepatol Int. 2024 Feb;18(1):296-298. doi: 10.1007/s12072-023-10597-8. Epub 2023 Oct 31.
9
Letter to the Editor: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect or residual confounding?致编辑的信：乙型肝炎肝硬化患者停止治疗的益处，是真实效果还是残余混杂因素？
Hepatology. 2024 Mar 1;79(3):E95-E96. doi: 10.1097/HEP.0000000000000639. Epub 2023 Oct 20.
10
Severity of Hepatitis B Relapse After Cessation of Nucleos(t)ide Analog: Need a Closer Look!核苷（酸）类似物停药后乙型肝炎复发的严重程度：需要进一步研究！
Clin Gastroenterol Hepatol. 2022 Aug;20(8):1885-1886. doi: 10.1016/j.cgh.2021.09.004. Epub 2021 Sep 9.
引用本文的文献
1
A critical review of diagnostic and prognostic markers of chronic hepatitis B infection.慢性乙型肝炎感染诊断和预后标志物的批判性综述。
Med Rev (2021). 2024 May 8;4(3):225-234. doi: 10.1515/mr-2024-0022. eCollection 2024 Jun.
本文引用的文献
1
Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B.慢性乙型肝炎重度急性发作后乙型肝炎表面抗原长期特征和血清学清除。
Gut Liver. 2023 Mar 15;17(2):280-287. doi: 10.5009/gnl220122. Epub 2022 Nov 1.
2
Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.HBsAg 血清学清除对乙型肝炎病毒相关肝细胞癌切除术后晚期复发的影响。
J Hepatol. 2022 Oct;77(4):939-946. doi: 10.1016/j.jhep.2022.05.014. Epub 2022 May 26.
3
Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).核苷（酸）类似物停药后慢性乙型肝炎患者的治疗应答变化：一项国际、多中心、多民族队列研究（RETRACT-B 研究）。
Gastroenterology. 2022 Mar;162(3):757-771.e4. doi: 10.1053/j.gastro.2021.11.002. Epub 2021 Nov 9.
4
Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.HBsAg 血清学清除后慢性乙型肝炎患者肝细胞癌的发生率：需要进行监测。
J Hepatol. 2015 May;62(5):1092-9. doi: 10.1016/j.jhep.2014.11.031. Epub 2014 Nov 28.
5
HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.核苷类似物治疗慢性乙型肝炎患者的 HBsAg 血清学清除：临床结局和持久性。
Gut. 2014 Aug;63(8):1325-32. doi: 10.1136/gutjnl-2013-305517. Epub 2013 Oct 25.
Zotero 插件